Cargando…
SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of STAT3...
Autores principales: | Su, Jung-Chen, Tseng, Ping-Hui, Wu, Szu-Hsien, Hsu, Cheng-Yi, Tai, Wei-Tien, Li, Yong-Shi, Chen, I-Ting, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198826/ https://www.ncbi.nlm.nih.gov/pubmed/25047655 http://dx.doi.org/10.1016/j.neo.2014.06.005 |
Ejemplares similares
-
RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014) -
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2013) -
Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017) -
Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
por: Su, Jung-Chen, et al.
Publicado: (2018) -
Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017)